Sugi Predict

Sugi Predict / Compounds / SCHEMBL57036

SCHEMBL57036

SCHEMBL57036

Cc1ccc(S(=O)(=O)OCCCF)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ GAA P10253 2/20 0.42
▸ PSMD10 O75832 1/20 0.42
▸ STAT3 P40763 1/20 0.41
▸ CYP24A1 Q07973 2/20 0.41
▸ G6PD P11413 1/20 0.41
▸ AGER Q15109 1/20 0.40
▸ CA2 P00918 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ VDR P11473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13020456 1.00 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL3838686 0.95 ALDH1A1 (0.43) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL2143227 0.93 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL10430736 0.93 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL8402278 0.93 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL2757584 0.89 GAA (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL71840 0.89 GAA (0.45) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL483847 0.89 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL890725 0.89 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19CA12
SCHEMBL8484861 0.87 ALDH1A1 (0.48) ALDH1A1CYP3A4CYP2C9CYP2C19CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744661-A2 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-20 — — EP disclosed
EP-4706123-A2 HALOGENATED ETHER-CONTAINING ELECTROLYTES Feon Energy, Inc. (US) 2026-03-11 — — EP disclosed
EP-4298092-B1 NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2025-11-26 — — EP disclosed
EP-4634190-A1 NOVEL COMPOUNDS FOR DIAGNOSIS AC Immune SA (CH) 2025-10-22 — — EP disclosed
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 — — US disclosed
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 — — US disclosed
WO-2024226580-A9 HALOGENATED ETHER-CONTAINING ELECTROLYTES FEON ENERGY, INC. (US) 2025-03-27 — — WO disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
WO-2024226580-A2 HALOGENATED ETHER-CONTAINING ELECTROLYTES FEON ENERGY, INC. (US) 2024-10-31 — — WO disclosed
US-20240360062-A1 HALOGENATED ETHER-CONTAINING ELECTROLYTES FEON ENERGY, INC. 2024-10-31 — — US disclosed
WO-2006040182-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 — — WO disclosed
WO-2006032911-A2 METALLOPROTEINASE INHIBITOR IMAGING AGENTS GE HEALTHCARE LIMITED (GB) 2006-03-30 — — WO disclosed
WO-2006016221-A1 OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-16 — — WO disclosed
WO-2006016220-A1 OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-02-16 — — WO disclosed
CN-1720050-A Improved imaging agents comprising barbituric acid derivatives AMERSHAM PLC (GB) 2006-01-11 — — CN disclosed
EP-1549317-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES GE Healthcare Limited (GB) 2005-07-06 — — EP disclosed
WO-2005053752-A2 NOVEL IMAGING AGENTS COMPRISING CASPASE-3 INHIBITORS GE HEALTHCARE LIMITED (GB) 2005-06-16 — — WO disclosed
WO-2005049005-A1 INHIBITOR IMAGING AGENTS GE HEALTHCARE LIMITED (GB) 2005-06-02 — — WO disclosed
US-20040097522-A1 Triazolopyrimidines BAYER CROPSCIENCE AG (DE) 2004-05-20 — — US disclosed
WO-2004032936-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES AMERSHAM PLC (GB) 2004-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH1A1 3040/4885CYP3A4 1947/4885CYP2C9 2669/4885
US-20240360062-A1 HALOGENATED ETHER-CONTAINING ELECTROLYTES SLC26A3, CLCN2, SLC26A4 ALDH1A1 662/4885CYP3A4 165/4885CYP2C9 148/4885
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH1A1 2699/4885CYP3A4 3843/4885CYP2C9 3416/4885
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 ALDH1A1 2527/4885CYP3A4 4371/4885CYP2C9 4740/4885
US-20040097522-A1 Triazolopyrimidines Q6ZSR9, CYP4X1, DDT ALDH1A1 373/4885CYP3A4 68/4885CYP2C9 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.